705 related articles for article (PubMed ID: 16022172)
1. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
2. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
3. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
Resche-Rigon M; Zohar S; Chevret S
Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
[TBL] [Abstract][Full Text] [Related]
4. An adaptive dose-finding design incorporating both toxicity and efficacy.
Zhang W; Sargent DJ; Mandrekar S
Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
[TBL] [Abstract][Full Text] [Related]
5. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
6. Improved designs for dose escalation studies using pharmacokinetic measurements.
Piantadosi S; Liu G
Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
[TBL] [Abstract][Full Text] [Related]
7. Statistical designs for early phases of cancer clinical trials.
Guan S
J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
[TBL] [Abstract][Full Text] [Related]
8. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
Wang SJ; Hung HM; O'Neill R
J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
[TBL] [Abstract][Full Text] [Related]
9. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
10. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.
Zohar S; Chevret S
J Biopharm Stat; 2003 Feb; 13(1):87-101. PubMed ID: 12635905
[TBL] [Abstract][Full Text] [Related]
11. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
Daimon T; Zohar S; O'Quigley J
Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
[TBL] [Abstract][Full Text] [Related]
12. A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities.
Su Z
Contemp Clin Trials; 2010 Jan; 31(1):105-7. PubMed ID: 19879974
[TBL] [Abstract][Full Text] [Related]
13. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
14. The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.
Yuan Z; Chappell R; Bailey H
Biometrics; 2007 Mar; 63(1):173-9. PubMed ID: 17447942
[TBL] [Abstract][Full Text] [Related]
15. Dose-finding in phase I clinical trials based on toxicity probability intervals.
Ji Y; Li Y; Nebiyou Bekele B
Clin Trials; 2007; 4(3):235-44. PubMed ID: 17715248
[TBL] [Abstract][Full Text] [Related]
16. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
Thall PF; Cook JD; Estey EH
J Biopharm Stat; 2006; 16(5):623-38. PubMed ID: 17037262
[TBL] [Abstract][Full Text] [Related]
17. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
Wang M; Day R
J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
19. Adaptive designs for dose-finding studies based on sigmoid Emax model.
Dragalin V; Hsuan F; Padmanabhan SK
J Biopharm Stat; 2007; 17(6):1051-70. PubMed ID: 18027216
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
